<DOC>
	<DOCNO>NCT00373815</DOCNO>
	<brief_summary>The present protocol dose-finding toxicity study preparation randomise study compare current standard treatment CSA/prednisolone new combination CSA/prednisolone/everolimus .</brief_summary>
	<brief_title>Everolimus Combination With Cyclosporine A Prednisolone Treatment Graft Versus Host Disease</brief_title>
	<detailed_description>The primary objective present study evaluate feasibility treatment everolimus combination CSA/prednisolone patient aGVHD allogeneic HSCT . This evaluation take account follow parameter : - Feasibility oral application everolimus - Daily dose needed reach target plasma level everolimus - Time reach target plasma level everolimusSecondary objectivesThe study evaluate toxicity safety treatment ever-olimus/CSA/prednisolone regard - Incidence severity treatment induce toxic event - Incidence , severity seriousness adverse event - Treatment induced morbidity - Treatment induced 1-year-mortality Furthermore study collect data - Efficacy everolimus/CSA/prednisolone aGVHD - Drug interaction everolimus CSA</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Written inform consent prior inclusion study Allogeneic HSCT HLAidentical relate unrelated donor Clinically confirm acute GVHD ≥ grade II Age &lt; 70 / &gt; 18 year , male female Karnofsky performance status &gt; 60 % Oral treatment feasible Severe hepatic impairment ChildPugh C Active cerebral epilepsy Renal failure ( Creatinine clearance &lt; 50 ml/min ) Life expectancy &lt; 3 month Known hypersensitivity everolimus , sirolimus excipients Confirmed pregnancy ( serum βHCG ) Noneffective contraception , male female patient , risk conception exist Patients limited legal capacity Patients unwilling unable undergo study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>acute GVHD</keyword>
	<keyword>Immunosuppression</keyword>
</DOC>